Caribou Biosciences Inc (CRBU)vsRegeneron Pharmaceuticals Inc (REGN)
CRBU
Caribou Biosciences Inc
$1.92
-7.02%
HEALTHCARE · Cap: $198.86M
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.46%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 133075% more annual revenue ($14.92B vs $11.20M). REGN leads profitability with a 29.6% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 64/100 (C+).
CRBU
Avoid23
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+45.5%
Fair Value
$2.92
Current Price
$1.92
$1.00 discount
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
1.9% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : CRBU
The strongest argument for CRBU centers on Debt/Equity, Price/Book.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : CRBU
The primary concerns for CRBU are Revenue Growth, EPS Growth, Market Cap.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
CRBU profiles as a value stock while REGN is a growth play — different risk/reward profiles.
CRBU carries more volatility with a beta of 2.33 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 23/100), backed by strong 29.6% margins and 19.0% revenue growth. CRBU offers better value entry with a 45.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caribou Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in cutting-edge genome editing technologies, particularly through its proprietary CRISPR platform. With a robust and diversified pipeline of innovative product candidates aimed at tackling urgent unmet medical needs in genetic disorders and oncology, the company is well-positioned to lead advancements in precision medicine. Leveraging strategic partnerships and a commitment to transformative research, Caribou aims to redefine treatment paradigms and significantly improve patient outcomes, establishing itself as a formidable entity in the biopharmaceutical sector.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?